New York State Common Retirement Fund Has $20.54 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

New York State Common Retirement Fund raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 208,503 shares of the medical equipment provider’s stock after buying an additional 41,538 shares during the quarter. New York State Common Retirement Fund’s holdings in Zimmer Biomet were worth $20,538,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ZBH. TD Waterhouse Canada Inc. raised its holdings in shares of Zimmer Biomet by 2,006.5% during the third quarter. TD Waterhouse Canada Inc. now owns 3,897 shares of the medical equipment provider’s stock valued at $385,000 after acquiring an additional 3,712 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Zimmer Biomet by 11.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,084 shares of the medical equipment provider’s stock valued at $2,963,000 after purchasing an additional 3,172 shares during the period. Valeo Financial Advisors LLC lifted its holdings in shares of Zimmer Biomet by 2.4% in the third quarter. Valeo Financial Advisors LLC now owns 12,713 shares of the medical equipment provider’s stock valued at $1,252,000 after purchasing an additional 304 shares in the last quarter. J. Safra Sarasin Holding AG boosted its position in shares of Zimmer Biomet by 93.1% in the third quarter. J. Safra Sarasin Holding AG now owns 12,415 shares of the medical equipment provider’s stock worth $1,223,000 after buying an additional 5,986 shares during the period. Finally, Belpointe Asset Management LLC grew its holdings in shares of Zimmer Biomet by 9.7% during the third quarter. Belpointe Asset Management LLC now owns 14,735 shares of the medical equipment provider’s stock valued at $1,451,000 after buying an additional 1,300 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH opened at $87.04 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The firm has a market cap of $17.25 billion, a PE ratio of 21.54, a PEG ratio of 2.19 and a beta of 0.62. The firm’s 50 day moving average price is $91.01 and its 200 day moving average price is $95.97. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ZBH shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. Canaccord Genuity Group reduced their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. BTIG Research restated a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a report on Thursday, January 8th. Royal Bank Of Canada dropped their price objective on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, November 6th. Finally, UBS Group cut their target price on shares of Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating for the company in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $107.24.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.